All News

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

Felix Guerrero-Ramos, MD, outlines molecular and pharmacologic findings from SunRISe-1, including the high prevalence of TP53 alterations and the extended drug exposure achieved with the TAR-200 intravesical delivery system.

Oncologist Thor Halfdanarson reviews dose-finding data for the targeted α radioligand therapy [^212Pb]VMT- α-NET, highlighting manageable toxicity, stable renal function, and plans for phase 2 evaluation.

New data from the NATALEE trial reveals ribociclib significantly improves invasive disease-free survival in HR+/HER2– early breast cancer.

Adjuvant abemaciclib plus endocrine therapy significantly enhances overall survival in high-risk HR-positive HER2-negative breast cancer.

Durvalumab combined with FLOT shows significant survival benefits for patients with resectable gastroesophageal junction cancer, regardless of PD-L1 status.

Students can better balance parenthood, academics, and self-care with planning, resilience, and strong support systems.

Novel mechanism offers hope for improved tolerability and efficacy in patients facing resistance or long-term toxicity with existing TKIs.

Pranav Garimella, MBBS, MPH, emphasizes that pharmacists are essential partners in managing chronic kidney disease, ensuring safe medication use, adherence, and coordinated care alongside physicians.

The expanded indications now include adolescents with hidradenitis suppurativa aged 12 and older and pediatrics with uveitis aged 2 and older.

Revised recommendations include new thresholds for initiating antihypertensive therapy using the PREVENT equation.

Nivolumab plus chemotherapy and ipilimumab show significant long-term survival benefits for advanced esophageal squamous cell carcinoma.

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.

The mean time intervals between injection and complete retinal vascularization were similar between the biosimilar and its reference product.

Three targeted inhibitors offer new strategies for HR-positive, HER2-negative breast cancer with PIK3CA mutations.

Individuals without a previous heart attack or stroke demonstrated significant cardiovascular risk reduction when treated with evolocumab.

Pharmacists are uniquely positioned to help prevent nutritional deficiencies, manage adverse effects, and maintain long-term health through tailored guidance.

Whether they are collaborating with other health care professionals, helping with medication adherence, or educating patients, pharmacists have a crucial role in every setting.

Charitable pharmacies provide essential medications to and address the health care needs of underserved populations.

Ron Lanton outlines enforcement uncertainty and downstream effects on biosimilars, specialty drugs, and pharmacy supply chains under most favored nation pricing proposals.

Explore the profound connection between emotions and oncology pharmacy, highlighting the importance of acknowledging feelings in patient care.

These negative effects were primarily presented when cells were stressed by inflammatory proteins in patients with chronic kidney disease (CKD) with APOL1 mutations.

The FDA approves a groundbreaking 1-minute HIV self-test, enhancing accessibility and empowering individuals to manage their health discreetly.

Explore how targeted therapies and immunotherapies transform oncology, highlighting novel antibody treatments and their impact on patient care and outcomes.

Steven Pipe, MD, highlights the growing importance of pharmacists in hemophilia care as new therapies expand treatment complexity and require specialized expertise.